Advancements in Treatment for Hypertrophic Cardiomyopathy: Key Considerations for Managed Care Professionals

Advancements in Treatment for Hypertrophic Cardiomyopathy: Key Considerations for Managed Care Professionals

Faculty

Ty J. Gluckman, MD
Medical Director
Center for Cardiovascular Analytics, Research and Data Science (CARDS)
Providence Heart Institute
Portland, Oregon

Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP
Vice President, Clinical Programs and Services
WellDyne
Lakeland, Florida

Medical Writing and Editorial Support

Brittany Hoffmann-Eubanks, PharmD, MBA
Owner
Banner Medical LLC
Frankfort, Illinois

Lori Uildriks, PharmD
Clinical Pharmacist/Clinical Instructor
Department of Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois
 
Program Description
Recent research into the unique pathophysiology in hypertrophic cardiomyopathy (HCM) has determined cellular mechanisms that initiate hypercontractility cause the heart muscle to become abnormally thick or enlarged, leading to progressive heart failure and reduced quality of life. There are many clinical manifestations of the disease that healthcare professionals should be able to identify, including its incidence across age cohorts and rate of mortality in certain presentations. As HCM is a genetic disease, indications for early genetic testing should be followed as later presentations have been misdiagnosed and are associated with more severe outcomes, such as sudden cardiac death. Current treatment for HCM consists of medications and surgical procedures reserved for specific presentations, but these do not address the underlying genetic defect. However, clinical trials are underway, with promising results for therapy options that do address the underlying pathology and contractile mechanism that would reduce hypercontractility in HCM. Managed care professionals should be prepared to consider the inclusion of these new therapy options in a disease state for which there are no current targeted therapies and complex hospital and post-discharge rehabilitation costs. This activity will examine their value to improve length and quality of life for people with HCM, as well as their role in mitigating other medical costs for these patients.

Target Audience: Managed care pharmacists
Type of Activity: Application
Release date: April 16, 2021
Expiration date: April 16, 2022
Time to complete activity: 2 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Analyze the pathophysiology, prevalence, risk factors, and incidence of hypertrophic cardiomyopathy (HCM).
• Examine recent updates to guideline recommendations of current treatments as well as updates on clinical studies on agents in development for HCM.
• Explore the clinical and economic burden of HCM and discuss disease management strategies to improve patient outcomes.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-21-154-H01-P. The activity is available for CE credit through April 16, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, read the online article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Faculty

Ty J. Gluckman, MD, and Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, have no relevant financial relationships with commercial interests to disclose.

Medical Writing and Editorial Support

Brittany Hoffmann-Eubanks, PharmD, MBA, and Lori Uildriks, PharmD, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kimberly Simpson, PharmD; Kelly McCormick; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Disclosure Policy
According to the disclosure policy of The American Journal of Managed Care® and Pharmacy Times Continuing Education™, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of Pharmacy Times Continuing Education™ to initiate a mechanism to resolve the conflict(s). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Disclosure of Unapproved/Off-Label Use
The contents of this activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Participants should note that the use of these products outside current approved labeling is considered experimental and they are advised to consult prescribing information for these products.

The information provided in this CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of The American Journal of Managed Care®, Pharmacy Times Continuing Education™, or the company that provided commercial support for this CE activity.

Signed disclosures are on file at the office of The American Journal of Managed Care®, Cranbury, New Jersey.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms